DOI:
10.1055/s-00000054
Pharmacopsychiatry
LinksClose Window
References
Ninan PT, Musgnung J, Messig M. et al.
Incidence and timing of taper/posttherapy-emergent adverse events following discontinuation of desvenlafaxine 50 mg/d in patients with major depressive disorder.
Prim Care Companion CNS Disord 2015; 17 doi:10.4088/PCC.14m01715
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.